Last reviewed · How we verify
DTaP-IPV mkc vaccine
DTaP-IPV mkc vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus through inactivated antigens.
DTaP-IPV mkc vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus through inactivated antigens. Used for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.
At a glance
| Generic name | DTaP-IPV mkc vaccine |
|---|---|
| Sponsor | Statens Serum Institut |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is a combination vaccine containing inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus particles. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize these pathogens if encountered naturally. The 'mkc' designation likely refers to the manufacturing cell substrate or process used by Statens Serum Institut.
Approved indications
- Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP-IPV mkc vaccine CI brief — competitive landscape report
- DTaP-IPV mkc vaccine updates RSS · CI watch RSS
- Statens Serum Institut portfolio CI